210 related articles for article (PubMed ID: 12553555)
1. Co-expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) in thyroid nodules is associated with co-expression of CD30 ligand/CD30 receptor.
Ruggeri RM; Villari D; Simone A; Scarfi R; Attard M; Orlandi F; Barresi G; Trimarchi F; Trovato M; Benvenga S
J Endocrinol Invest; 2002 Dec; 25(11):959-66. PubMed ID: 12553555
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD30 ligand and CD30 receptor in normal thyroid and benign and malignant thyroid nodules.
Trovato M; Villari D; Ruggeri RM; Quattrocchi E; Fragetta F; Simone A; Scarfi R; Magro G; Batolo D; Trimarchi F; Benvenga S
Thyroid; 2001 Jul; 11(7):621-8. PubMed ID: 11484890
[TBL] [Abstract][Full Text] [Related]
3. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules.
Trovato M; Villari D; Bartolone L; Spinella S; Simone A; Violi MA; Trimarchi F; Batolo D; Benvenga S
Thyroid; 1998 Feb; 8(2):125-31. PubMed ID: 9510120
[TBL] [Abstract][Full Text] [Related]
4. Distinctive expression of STAT3 in papillary thyroid carcinomas and a subset of follicular adenomas.
Trovato M; Grosso M; Vitarelli E; Ruggeri RM; Alesci S; Trimarchi F; Barresi G; Benvenga S
Histol Histopathol; 2003 Apr; 18(2):393-9. PubMed ID: 12647789
[TBL] [Abstract][Full Text] [Related]
5. HGF/C-MET system pathways in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization.
Ruggeri RM; Vitarelli E; Barresi G; Trimarchi F; Benvenga S; Trovato M
Histol Histopathol; 2012 Jan; 27(1):113-21. PubMed ID: 22127603
[TBL] [Abstract][Full Text] [Related]
6. Immunoexpression of the CD30 ligand/CD30 and IL-6/IL-6R signals in thyroid autoimmune diseases.
Ruggeri RM; Barresi G; Sciacchitano S; Trimarchi F; Benvenga S; Trovato M
Histol Histopathol; 2006 Mar; 21(3):249-56. PubMed ID: 16372246
[TBL] [Abstract][Full Text] [Related]
7. Loss of heterozygosity of the long arm of chromosome 7 in follicular and anaplastic thyroid cancer, but not in papillary thyroid cancer.
Trovato M; Fraggetta F; Villari D; Batolo D; Mackey K; Trimarchi F; Benvenga S
J Clin Endocrinol Metab; 1999 Sep; 84(9):3235-40. PubMed ID: 10487693
[TBL] [Abstract][Full Text] [Related]
8. Co-expression of CD30 ligand and interleukin 4 (IL-4) receptors by acute myeloid leukaemia blasts is associated with the expansion of IL-4-producing CD30+ normal T cells.
Rossi FM; Degan M; Mazzocco FT; Di Francia R; Aldinucci D; Poletto D; Vellenga E; Pinto A; Gattei V
Br J Haematol; 2002 Apr; 117(1):59-69. PubMed ID: 11918534
[TBL] [Abstract][Full Text] [Related]
9. Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents.
Patel A; Jhiang S; Dogra S; Terrell R; Powers PA; Fenton C; Dinauer CA; Tuttle RM; Francis GL
Pediatr Res; 2002 Nov; 52(5):737-44. PubMed ID: 12409522
[TBL] [Abstract][Full Text] [Related]
10. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.
Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A
Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634
[TBL] [Abstract][Full Text] [Related]
11. uPA receptor expression in benign and malignant thyroid tumors.
Kim SJ; Shiba E; Taguchi T; Tsukamoto F; Miyoshi Y; Tanji Y; Takai S; Noguchi S
Anticancer Res; 2002; 22(1A):387-93. PubMed ID: 12017319
[TBL] [Abstract][Full Text] [Related]
12. Reverse signaling via CD30 ligand.
Wiley SR; Goodwin RG; Smith CA
J Immunol; 1996 Oct; 157(8):3635-9. PubMed ID: 8871664
[TBL] [Abstract][Full Text] [Related]
13. Immunocytochemical localisation of interleukin-1 alpha and interleukin-6 in thyroid tissues from patients with neoplastic or autoimmune thyroid disorders.
Kayser L; Broholm H; Francis D; Perrild H; Olsen BE; Bendtzen K; Høyer PE
Autoimmunity; 1995; 20(2):75-82. PubMed ID: 7578871
[TBL] [Abstract][Full Text] [Related]
14. CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice.
Sun X; Yamada H; Shibata K; Muta H; Tani K; Podack ER; Yoshikai Y
J Immunol; 2010 Aug; 185(4):2222-30. PubMed ID: 20639486
[TBL] [Abstract][Full Text] [Related]
15. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.
Gruss HJ; DaSilva N; Hu ZB; Uphoff CC; Goodwin RG; Drexler HG
Leukemia; 1994 Dec; 8(12):2083-94. PubMed ID: 7528856
[TBL] [Abstract][Full Text] [Related]
16. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.
Gruss HJ; Pinto A; Gloghini A; Wehnes E; Wright B; Boiani N; Aldinucci D; Gattei V; Zagonel V; Smith CA; Kadin ME; von Schilling C; Goodwin RG; Herrmann F; Carbone A
Am J Pathol; 1996 Aug; 149(2):469-81. PubMed ID: 8701986
[TBL] [Abstract][Full Text] [Related]
17. CD57 (Leu-7) expression is helpful in diagnosis of the follicular variant of papillary thyroid carcinoma.
Khan A; Baker SP; Patwardhan NA; Pullman JM
Virchows Arch; 1998 May; 432(5):427-32. PubMed ID: 9645441
[TBL] [Abstract][Full Text] [Related]
18. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.
Saggiorato E; Aversa S; Deandreis D; Arecco F; Mussa A; Puligheddu B; Cappia S; Conticello S; Papotti M; Orlandi F
J Endocrinol Invest; 2004 Apr; 27(4):311-7. PubMed ID: 15233548
[TBL] [Abstract][Full Text] [Related]
19. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.
Raphael SJ; McKeown-Eyssen G; Asa SL
Mod Pathol; 1994 Apr; 7(3):295-300. PubMed ID: 7520169
[TBL] [Abstract][Full Text] [Related]
20. Expression of c-kit, Flk-1, and Flk-2 receptors in benign and malignant tumors of follicular epithelial origin.
Kung SP; Lee CH; Yang AH; Chi CW; Tseng LM; Wu CW
J Chin Med Assoc; 2006 Feb; 69(2):74-9. PubMed ID: 16570574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
